Skin barrier-inflammatory pathway is a driver of the psoriasis-atopic dermatitis transition

As chronic inflammatory conditions driven by immune dysregulation are influenced by genetics and environment factors, psoriasis and atopic dermatitis (AD) have traditionally been considered to be distinct diseases characterized by different T cell responses. Psoriasis, associated with type 17 helper...

Full description

Saved in:
Bibliographic Details
Published inFrontiers in medicine Vol. 11; p. 1335551
Main Authors Dong, Sitan, Li, Dongmei, Shi, Dongmei
Format Journal Article
LanguageEnglish
Published Switzerland Frontiers Media S.A 28.03.2024
Subjects
antimicrobial peptides
atopic dermatitis
Medicine
overlap
psoriasis
skin barrier
tissue-resident memory T cell
skin barrier
atopic dermatitis
overlap
tissue-resident memory T cell
psoriasis
antimicrobial peptides
Online AccessGet full text

Cover

More Information
Summary:As chronic inflammatory conditions driven by immune dysregulation are influenced by genetics and environment factors, psoriasis and atopic dermatitis (AD) have traditionally been considered to be distinct diseases characterized by different T cell responses. Psoriasis, associated with type 17 helper T (Th17)-mediated inflammation, presents as well-defined scaly plaques with minimal pruritus. AD, primarily linked to Th2-mediated inflammation, presents with poorly defined erythema, dry skin, and intense itching. However, psoriasis and AD may overlap or transition into one another spontaneously, independent of biological agent usage. Emerging evidence suggests that defects in skin barrier-related molecules interact with the polarization of T cells, which forms a skin barrier-inflammatory loop with them. This loop contributes to the chronicity of the primary disease or the transition between psoriasis and AD. This review aimed to elucidate the mechanisms underlying skin barrier defects in driving the overlap between psoriasis and AD. In this review, the importance of repairing the skin barrier was underscored, and the significance of tailoring biologic treatments based on individual immune status instead of solely adhering to the treatment guidelines for AD or psoriasis was emphasized.
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-3
content type line 23
ObjectType-Review-1
Edited by: Zhenghua Zhang, Huashan Hospital, Fudan University, China
Reviewed by: Zlatko Kopecki, University of South Australia, Australia
Francois Niyonsaba, Juntendo University, Japan
ISSN:2296-858X
2296-858X
DOI:10.3389/fmed.2024.1335551